Finally, an important consideration is that this study only analyzes efficacy for combined BRAF and MEK inhibition, in future study toxic effects should be evaluated when comparing those targeted therapies, such as the incidence of pyrexia [31], panniculitis [32], gastrointestinal or ocular toxicity cutaneous adverse events [33]. The gene discussed is BRAF; the disease is panniculitis.